NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,155 | -72.2% | 17,050 | -73.1% | 0.00% | – |
| Q2 2023 | $36,474 | -81.1% | 63,411 | +343.2% | 0.00% | – |
| Q4 2021 | $193,000 | -26.3% | 14,309 | -1.8% | 0.00% | – |
| Q3 2021 | $262,000 | +12.4% | 14,568 | +7.4% | 0.00% | – |
| Q2 2021 | $233,000 | -30.2% | 13,564 | -18.8% | 0.00% | – |
| Q1 2021 | $334,000 | +63.7% | 16,710 | +39.1% | 0.00% | – |
| Q4 2020 | $204,000 | -16.4% | 12,010 | +74.9% | 0.00% | – |
| Q2 2019 | $244,000 | -0.8% | 6,868 | -6.3% | 0.00% | – |
| Q1 2019 | $246,000 | -3.1% | 7,331 | -5.2% | 0.00% | – |
| Q4 2018 | $254,000 | -93.6% | 7,736 | -88.1% | 0.00% | -100.0% |
| Q3 2018 | $3,971,000 | +8348.9% | 65,136 | +6499.4% | 0.01% | – |
| Q2 2018 | $47,000 | -56.9% | 987 | -8.3% | 0.00% | – |
| Q1 2018 | $109,000 | +113.7% | 1,076 | +25.4% | 0.00% | – |
| Q4 2017 | $51,000 | +5000.0% | 858 | +946.3% | 0.00% | – |
| Q4 2016 | $1,000 | – | 82 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |